{"id":"W1947519512","doi":"10.1007/s40273-015-0332-5","title":"Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada","year":2015,"lang":"en","type":"article","venue":"PharmacoEconomics","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"Health Canada; Novartis Pharmaceuticals Canada; GlaxoSmithKline","keywords":"Chlorambucil; Ofatumumab; Medicine; Fludarabine; Quality-adjusted life year; Cost effectiveness; Life expectancy; Actuarial science; Internal medicine; Chronic lymphocytic leukemia; Population; Chemotherapy; Leukemia; Environmental health; Economics","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001172584,0.0002744395,0.0008564625,0.0002850768,0.00002043385,0.00001283365,0.0003148029,0.0001038001,0.0001237934],"category_scores_gemma":[0.0002173152,0.0002914909,0.00007665306,0.0003896097,0.0001127804,0.0001588348,0.0001780124,0.000383284,0.00005546295],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.4639516,"about_ca_system_score_gemma":0.2042492,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.8963996,"about_ca_topic_score_gemma":0.84821,"domain_scores_codex":[0.99765,0.0001348983,0.000729125,0.0004693598,0.0003222177,0.0006944344],"domain_scores_gemma":[0.9983084,0.0005494795,0.000150003,0.0004534008,0.0001201586,0.0004185778],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.01401339,0.0003320286,0.04214622,0.005215346,0.000325981,0.002044307,0.0009288828,0.9175071,0.002178228,0.0002100462,0.002649167,0.01244929],"study_design_scores_gemma":[0.1410857,0.0002339548,0.003848233,0.0005933662,0.00005920761,0.0002085816,0.0001869324,0.8067195,0.04262493,0.00009249694,0.00394812,0.0003989282],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948959,0.001511057,0.00003402618,0.0001224004,0.0004522189,0.001280228,0.00003639212,0.00001808161,0.0016497],"genre_scores_gemma":[0.9988041,0.0004931311,0.00003573241,0.0001824597,0.0001456339,0.0001428082,0.00005254304,0.00005425288,0.00008936186],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2597024,"threshold_uncertainty_score":0.9999537,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07660397386840974,"score_gpt":0.3576827904738943,"score_spread":0.2810788166054846,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}